Repatha Traveling While on This Drug: A Complete Practical Guide

What Repatha Is and Why Consistent Dosing Matters During Travel

Evolocumab (Repatha) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on hepatocytes. By blocking PCSK9, the drug preserves receptor recycling and drives LDL-C out of plasma. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statin therapy. 1

Why Missing a Dose Has Real Consequences

The cardiovascular benefit of evolocumab depends on sustained LDL-C suppression. In the FOURIER trial (N=27,564 patients with established ASCVD), semaglutide-class PCSK9 inhibitors reduced the composite of MI, stroke, and CV death by 15% over a median 2.2 years, with benefits tracking closely to time-averaged LDL-C exposure. 2 A single skipped dose transiently allows LDL-C to rebound. For patients with HoFH, in whom baseline LDL-C may exceed 400 mg/dL, that rebound is more pronounced and clinically relevant. 3

Who Is Most at Risk From Dosing Gaps

Patients with HoFH or recent acute coronary syndrome are the two groups for whom maintaining schedule during travel matters most. The GLAGOV intravascular ultrasound sub-study (N=968) showed that patients achieving mean LDL-C of 36.6 mg/dL on evolocumab had measurable plaque regression at 78 weeks. 4 Interrupting therapy even briefly may slow that regression trajectory.

Practical rule: if you are on the 140 mg every-2-week regimen and your next dose falls within your travel window, inject before departure if departure is within 3 days of your scheduled date, or plan injection supplies for the trip itself.

Repatha Storage During Travel: Cold Chain Facts

Repatha must be refrigerated at 36°F to 46°F (2°C to 8°C) under normal home storage conditions. Amgen's FDA-approved prescribing information states the device may be stored at room temperature up to 77°F (25°C) for a single cumulative period not exceeding 30 days. Once removed from refrigeration, the 30-day clock cannot be reset. 1

Keeping It Cold on Flights

• Use an insulated medical-grade travel cooler with a gel pack. Avoid dry ice for air travel; FAA regulations limit dry ice to 5.5 lb (2.5 kg) and require notification to airline staff. 5
• Place the autoinjector in the cooler inside your carry-on bag, never in checked luggage. Cargo hold temperatures are unregulated and can drop well below freezing, which damages biologic formulations. Amgen's label explicitly states the product must not be frozen. 1
• Gel packs approved for carry-on are subject to TSA officer discretion, but TSA policy states that ice packs in any state of melt are permitted for medical purposes in carry-on bags. 6

Hotel and Rental Storage

Most hotel room minibars maintain 35°F to 46°F. Ask the front desk to confirm the temperature before placing the device inside. A small digital thermometer (less than $10) can be packed to verify. If a minifridge is unavailable, the 30-day room-temperature window applies, provided the ambient temperature stays at or below 77°F. Destinations with sustained heat above 77°F, such as tropical climates in summer, require a portable cooler solution.

When the Cold Chain Breaks

Do not inject a device that has been frozen or that has been above 77°F for more than 30 cumulative days. The FDA MedWatch guidance on biologic storage breaches advises contacting the manufacturer or pharmacist before using any temperature-compromised biologic. 7 Amgen's 24/7 patient support line (1-844-737-2842) can advise on individual storage events.

TSA Rules and International Customs for Repatha

U.S. Domestic Flights

The Transportation Security Administration exempts medically necessary liquids, gels, and injectables from the standard 3.4-oz (100 mL) limit. This explicitly covers prefilled syringes and autoinjectors. 6 Declare the device and any accompanying gel packs at the checkpoint before screening begins. Carrying the original pharmacy label and a brief prescriber letter shortens the checkpoint interaction to under two minutes in most cases.

International Travel

Import rules for biologic injectables vary significantly. The European Medicines Agency authorized evolocumab (brand: Repatha) across EU member states; carrying a translated prescriber letter and the original pharmacy packaging satisfies customs requirements in most EU countries. 8 For travel to countries where Repatha may not be locally registered, the quantity carried must typically not exceed a 90-day personal supply, and some nations require an import permit.

Specific country rules:

• Japan: Personal import of biologic drugs for personal use generally requires a Yakkan Shoumei import certificate for quantities above a one-month supply.
• Canada: Health Canada permits personal importation of a 90-day supply of prescription medications with proper documentation.
• Australia: The Therapeutic Goods Administration allows personal importation of up to a 3-month supply with a valid prescription.

Carry at minimum: original labeled packaging, prescriber letter on clinic letterhead, and your most recent lipid panel for customs officials who may question the clinical necessity.

The HealthRX Travel Readiness Checklist for Repatha users (developed with our clinical pharmacist team) organizes preparation into four phases: 30 days before departure, 7 days before, day of travel, and at destination. This framework is designed to prevent the three most common travel-related medication errors our physicians see: dose timing confusion across time zones, cold-chain failure in checked luggage, and failure to carry enough supply for trip extensions.

Injection Timing Across Time Zones

Evolocumab's pharmacokinetics support dose-date flexibility. The drug has a half-life of approximately 11 to 17 days. 9 This long half-life means a shift of 24 to 48 hours in injection timing has no detectable effect on steady-state LDL-C suppression. The Amgen prescribing information confirms that for the Q2W regimen, if a dose is missed, it should be administered as soon as possible. If the next scheduled dose is more than 7 days away, inject the missed dose. If the next dose is within 7 days, skip the missed dose and resume the regular schedule. 1

Crossing Multiple Time Zones

For eastward travel crossing 6 or more time zones, the injected calendar date may shift by one day. Because the 14-day dosing window has a built-in 7-day buffer in either direction, this shift is pharmacologically inconsequential. Track your dose date in your phone calendar using the local time zone at your destination, and update it on return.

The Monthly 420 mg Regimen

The Pushtronex on-body infusor delivers 420 mg over approximately 9 minutes once monthly. For travel, some patients prefer switching temporarily to three consecutive 140 mg injections given on the same day or over 30 minutes. Confirm this with your prescriber before departure; the prescribing information permits both approaches. 1

Living With Repatha Day to Day

Injection Technique and Site Rotation

Subcutaneous injections go into the abdomen (at least 2 inches from the navel), the outer thigh, or the upper arm. Rotating sites reduces local lipodystrophy and injection-site reactions. In the DESCARTES trial (N=901, 52 weeks), injection-site reactions occurred in 4.3% of evolocumab-treated patients vs. 4.8% placebo, confirming the reaction rate is low enough that it rarely disrupts daily activities. 10

Warm the device to room temperature for at least 30 minutes before injecting. Cold devices produce more discomfort. Do not rub the injection site after injection; gentle pressure with a cotton ball is sufficient.

Exercise and Physical Activity

No exercise restrictions apply to evolocumab users. The ACC/AHA 2018 Cholesterol Guideline recommends lifestyle modification, including 150 minutes per week of moderate-intensity aerobic activity, as a cornerstone of ASCVD risk reduction, with PCSK9 inhibitors added for patients who remain above LDL-C thresholds despite statin therapy and lifestyle change. 11 Strenuous exercise the day of injection does not affect absorption or efficacy.

Diet Interactions

Evolocumab has no food interactions. Unlike some small-molecule drugs, monoclonal antibodies are not substrates of cytochrome P450 enzymes and are not affected by dietary components such as grapefruit. 9 Continuing a heart-healthy dietary pattern, specifically one aligned with the Mediterranean or DASH dietary approach as supported by AHA guidelines, compounds the LDL-C-lowering effect by reducing hepatic cholesterol synthesis. 12

Drug Interactions While Traveling

The most common travel-related medication scenario is starting a short course of an antibiotic or anti-malarial drug. Evolocumab has no known pharmacokinetic drug interactions; however, patients adding a statin or increasing statin dose during travel should notify their prescriber on return for a lipid panel recheck, since statin dose adjustments alter the baseline LDL-C from which evolocumab's additive benefit is calculated. 1

Special Travel Scenarios

Cruises

Cruise ship medical facilities carry limited biologics inventory. Request a signed medical letter from your cardiologist or lipidologist stating the drug name, dose, and clinical indication. Pack a minimum of two additional doses beyond what you calculate you need for the trip. Cruise itineraries to tropical destinations require particular attention to the 77°F storage limit; store the device in the cabin minibar or a portable cooler rather than on deck.

High-Altitude Destinations

No pharmacokinetic data suggest altitude affects evolocumab absorption or clearance. Subcutaneous absorption may be marginally faster at altitude due to increased peripheral blood flow, but this effect is not clinically significant given the drug's long half-life of 11 to 17 days. 9

Traveling With Familial Hypercholesterolemia

Patients with HeFH have a roughly 20-fold higher prevalence of premature coronary artery disease compared with the general population, as cited in the European Atherosclerosis Society Consensus Statement. 13 For these patients, travel to destinations with limited emergency cardiac care requires extra planning: carry your most recent echocardiogram or stress test report, maintain an updated medication list, and confirm travel insurance covers cardiac events.

The ACC/AHA 2018 guideline states: "For patients with LDL-C levels persistently 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add a PCSK9 inhibitor, particularly in very high-risk ASCVD patients." 11 Maintaining that PCSK9 inhibitor throughout travel is not optional for this risk group.

Sharps Disposal During Travel

The FDA recommends disposing of used needles and autoinjectors in an FDA-cleared sharps container. On the road, the FDA sharps safety guidance advises using a heavy-duty plastic container with a lid, such as a detergent bottle, when a proper sharps container is unavailable. 14 Airlines prohibit placing used sharps in aircraft trash. Take them home in a sealed container and dispose at a local sharps collection site. Find locations at SafeNeedleDisposal.org or through your state health department. 15

Monitoring LDL-C Around Travel

A lipid panel 4 to 12 weeks after starting or restarting evolocumab, and at least annually once stable, is standard practice per ACC/AHA guidelines. 11 If a trip causes a confirmed missed dose or a cold-chain event requiring dose replacement, request a repeat lipid panel 4 to 6 weeks after resuming the regular schedule.

Reference point: in the FOURIER trial, the mean LDL-C on evolocumab was 30 mg/dL vs. 92 mg/dL placebo at week 48. 2 Any trip-related gap that pushes your LDL-C back above your individual target warrants a call to your prescriber before the next scheduled appointment.

Patients achieving very low LDL-C (<25 mg/dL) do not need to adjust travel plans based on lipid targets alone; current evidence from the FOURIER and ODYSSEY OUTCOMES trials does not show adverse neurological or hormonal effects at these levels. 16